ONCOLYTICS BIOTECH INC
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
Country Alberta, Canada
Business Address 804, 322 - 11 AVENUE SW, CALGARY, ,
Mailing Address 804, 322 - 11 AVENUE SW, CALGARY, ,
Phone 4036707377
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2025
$13.42M
Total Assets
$11.08M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 20, 2026 | View on SEC |
| 8-K Current report of material events | March 19, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| 8-K Current report of material events | February 24, 2026 | View on SEC |
| 4 Insider stock transaction report | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | February 13, 2026 | View on SEC |
Annual Reports
10-K March 30, 2026
- Developing pelareorep, a proprietary non-pathogenic virus for cancer immunotherapy.
- Positive clinical data from the GOBLET study in pancreatic cancer patients.
Insider Trading
BUY 10 insiders
14 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.